Skip to main content

Research Repository

Advanced Search

The endocannabinoid anandamide causes endothelium-dependent vasorelaxation in human mesenteric arteries

Stanley, Christopher P.; Hind, William H.; Tufarelli, Christina; O'Sullivan, Saoirse

The endocannabinoid anandamide causes endothelium-dependent vasorelaxation in human mesenteric arteries Thumbnail


Authors

Christopher P. Stanley

William H. Hind

Christina Tufarelli

Saoirse O'Sullivan



Abstract

The endocannabinoid anandamide (AEA) causes vasorelaxation in animal studies. Although circulating AEA levels are increased in many pathologies, little is known about its vascular effects in humans. The aim of this work was to characterise the effects of AEA in human arteries. Ethical approval was granted to obtain mesenteric arteries from patients (n = 31) undergoing bowel resection. Wire myography was used to probe the effects and mechanisms of action of AEA. RT?PCR was used to confirm the presence of receptor mRNA in human aortic endothelial cells (HAECs) and intracellular signalling proteins were measured using multiplex technology. AEA caused vasorelaxation of precontracted human mesenteric arteries with an Rmax of ?30%. A synthetic CB1 agonist (CP55940) caused greater vasorelaxation (Rmax ?60%) while a CB2 receptor agonist (HU308) had no effect on vascular tone. AEA-induced vasorelaxation was inhibited by removing the endothelium, inhibition of nitric oxide (NO) synthase, antagonising the CB1 receptor and antagonising the proposed novel endothelial cannabinoid receptor (CBe). AEA?induced vasorelaxation was not affected by CB2 antagonism, by depleting sensory neurotransmitters, or inhibiting cyclooxygenase activity. RT?PCR showed CB1 but not CB2 receptors were present in HAECs, and AEA and CP55940 had similar profiles in HAECs (increased phosphorylation of JNK, NF?B, ERK, Akt, p70s6K, STAT3 and STAT5). Post hoc analysis of the data set showed that overweight patients and those taking paracetamol had reduced vasorelaxant responses to AEA. These data show that AEA causes moderate endothelium-dependent, NO-dependent vasorelaxation in human mesenteric arteries via activation of CB1 receptors.

Citation

Stanley, C. P., Hind, W. H., Tufarelli, C., & O'Sullivan, S. (2016). The endocannabinoid anandamide causes endothelium-dependent vasorelaxation in human mesenteric arteries. Pharmacological Research, 113(A), 356-363. https://doi.org/10.1016/j.phrs.2016.08.028

Journal Article Type Article
Acceptance Date Aug 27, 2016
Online Publication Date Sep 12, 2016
Publication Date Nov 1, 2016
Deposit Date Nov 23, 2016
Publicly Available Date Nov 23, 2016
Journal Pharmacological Research
Print ISSN 1043-6618
Electronic ISSN 10436618
Publisher Elsevier
Peer Reviewed Peer Reviewed
Volume 113
Issue A
Pages 356-363
DOI https://doi.org/10.1016/j.phrs.2016.08.028
Keywords Cannabinoid; Anandamide; Vasorelaxation; Human; Mesenteric artery; CB1; Endothelium; Obesity; Paracetamol
Public URL https://nottingham-repository.worktribe.com/output/974458
Publisher URL http://www.sciencedirect.com/science/article/pii/S104366181630113X
Additional Information This article is maintained by: Elsevier; Article Title: The endocannabinoid anandamide causes endothelium-dependent vasorelaxation in human mesenteric arteries; Journal Title: Pharmacological Research; CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.phrs.2016.08.028; Content Type: article; Copyright: © 2016 The Authors. Published by Elsevier Ltd.

Files




Downloadable Citations